Brokerages Set Arcus Biosciences, Inc. (NYSE:RCUS) PT at $33.67

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have received an average recommendation of “Buy” from the ten brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $34.13.

RCUS has been the topic of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd. Barclays raised their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Wells Fargo & Company assumed coverage on Arcus Biosciences in a research report on Tuesday, October 8th. They set an “overweight” rating and a $29.00 target price for the company. Wedbush reissued an “outperform” rating and issued a $36.00 price objective on shares of Arcus Biosciences in a research report on Thursday, November 7th. Finally, Evercore ISI raised Arcus Biosciences to a “strong-buy” rating in a research report on Friday, August 9th.

Hedge Funds Weigh In On Arcus Biosciences

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Arcus Biosciences by 2.4% during the first quarter. Vanguard Group Inc. now owns 4,791,244 shares of the company’s stock valued at $90,459,000 after buying an additional 110,528 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of Arcus Biosciences by 25.1% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company’s stock worth $14,236,000 after purchasing an additional 186,750 shares during the last quarter. Nordea Investment Management AB lifted its position in shares of Arcus Biosciences by 26.3% during the first quarter. Nordea Investment Management AB now owns 259,372 shares of the company’s stock worth $4,892,000 after purchasing an additional 53,944 shares during the last quarter. GSA Capital Partners LLP lifted its position in shares of Arcus Biosciences by 17.8% during the third quarter. GSA Capital Partners LLP now owns 187,415 shares of the company’s stock worth $2,866,000 after purchasing an additional 28,307 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of Arcus Biosciences by 1,396.1% during the second quarter. SG Americas Securities LLC now owns 129,292 shares of the company’s stock worth $1,969,000 after purchasing an additional 120,650 shares during the last quarter. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Trading Down 0.6 %

NYSE RCUS opened at $17.74 on Thursday. The stock has a 50-day simple moving average of $16.62 and a 200 day simple moving average of $16.09. The company has a market capitalization of $1.62 billion, a PE ratio of -5.63 and a beta of 0.89. The company has a current ratio of 5.24, a quick ratio of 5.14 and a debt-to-equity ratio of 0.08. Arcus Biosciences has a 12 month low of $12.95 and a 12 month high of $20.31.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.06. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The firm had revenue of $48.00 million during the quarter, compared to analysts’ expectations of $38.95 million. During the same period in the prior year, the firm posted ($0.94) earnings per share. The business’s quarterly revenue was up 50.0% compared to the same quarter last year. Research analysts forecast that Arcus Biosciences will post -3.25 EPS for the current year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.